A Roadmap to Nonhematopoietic Stem Cell-Based Therapeutics

Xiao-Dong Chen, M.D., Ph.D. is currently a Professor in the Department of Comprehensive Dentistry and Chief of the Regenerative Medicine Program in the School of Dentistry at the University of Texas Health Science Center at San Antonio. He is also the founder and Chief Scientific Officer of StemBioSys, Inc., San Antonio, Texas and a Visiting Professor at Shanghai Jiao-Tong University School of Medicine.Dr. Chen received his M.D. from Shanghai Jiao-Tong University School of Medicine, subsequently entered General Surgery residency, and then served as a staff General Surgeon. He also has a Ph.D. in Hematology and Developmental Immunology and has pursued the study of mesenchymal stem cells (MSCs) since 1993. He received post-doctoral training in stem cell and skeletal biology at Yale University and the National Institute of Dental and Craniofacial Research (NIDCR) in Bethesda, Maryland. Dr Chen’s group was the first to establish a culture system, using cell-free native ECM, for expanding large numbers of high-quality non-hematopoietic stem cells (NHSCs) from various sources. To closely replicate the tissue specific microenvironment (niche) ex vivo, Dr. Chen and his team have extended their technology and developed 3D tissue-specific matrices for use in a variety of stem cell-based applications such as: 1) rejuvenating NHSCs from the elderly to establish a personal stem cell bank containing large numbers of high-quality autologous cells for treating age-related diseases; 2) inducing NHSC differentiation into the salivary gland epithelial cell lineage for repairing damaged salivary gland; and 3) enhancing the efficacy of bone marrow-derived MSCs for treating community-acquired pneumonia. The cell culture technology has also been used for other applications such as preserving pancreatic islet function, while reducing islet immunogenicity, for use in islet transplantation to treat type 1 diabetes. To foster the translation of his laboratory discoveries, Dr. Chen co-founded a startup company in 2010 (StemBioSys, Inc.; www.stembiosys.com). During the last several years, the company has been developing technology for scaling up the production of stem cells for treating human diseases, and providing a unique platform for quickly developing broad collaborations with other research institutes and biotech companies for basic research and clinical applications.

• Part 1 Principles and Concepts1. What Can We Learn From This Book?Travis J. Block, David D. Dean and Xiao-Dong Chen2. Features of Mesenchymal Stem CellsStan Gronthos3. Maintenance and Culture of  MSCsMilos Marinkovic, David D. Dean and Xiao-Dong Chen4. Manufacturing Mesenchymal Stromal Cell BanksJamie Hoover and Patrick J. HanleyPart 2 Promises and Challenges of MSC-Based Therapies5. Mesenchymal Stem Cell-Based Therapy of Osteoarthritis: Current Clinical Developments and Future Therapeutic StrategiesMaxime Ruiz, Marie Maumus, Christian Jorgensen and Daniele Noel6. Mesenchymal Stem Cell Therapy in Graft Versus Host DiseaseShivaprasad Manjappa, Rizwan Romee and Armin Rashidi7. Systemic Lupus ErythematosusDandan Wang and Lingyun Sun8. Mesenchymal Stem Cell-Based Therapies for Repair and Regeneration of Skin WoundsShanmugasundaram Natesan, Randolph Stone, Rodney K. Chan and Robert J. Christy9. Myocardial InfarctionNatalia Rozwadowska and Maciej Kurpisz10. Bone Marrow Mesenchymal Stem Cells as a New Therapeutic Approach for Diabetes MellitusJoseph Kim, John Z. Q. Luo and Luguang Luo11. Mesenchymal Stem Cell-Based Therapy for Chronic Kidney DiseaseMaria V. Irazabal, LaTonya J. Hickson and Alfonso Eirin12. Promises and Challenges of MSC-Based Therapies: Parkinson Disease and ParkinsonismAshley Aaroe and Claire Henchcliffe13. Spinal Cord InjuryK. A. Ruppert, S. D. Olson and C. S. Cox14. Stem Cell-Based Restoration of Salivary Gland FunctionOlivia N. Tran, Hanzhou Wang, David D. Dean, Xiao-Dong Chen and Chih-Ko Yeh15. Tooth and Dental Pulp RegenerationBei Li, Chen Xi and Yan JinPart 3: Future Perspectives 16. MSCs as Biological DrugsThekkeparambil Chandrabose Srijaya, Sandhya Sriram, Noor Hayaty Abu Kasim and Shigeki Sugii17. Mesenchymal Stem Cell-Derived Products for Tissue Repair and RegenerationAnand Srinivasan, Michelle Lynn Fults, Peter Supronowicz, Roberto Esquivel and Rogelio Zamilpa18. Use of MSCs in Antiaging StrategiesTravis J. Block, David D. Dean and Xiao-Dong Chen19. Regulatory Developments for Nonhematopoietic Stem Cell Therapeutics: Perspectives From the EU, the USA, Japan, China, India, Argentina, and BrazilAchim Rosemann, Gabriela Bortz and Federico Vasen